Article
Multidisciplinary Sciences
Margaret Ndinguri, Lisa Middleton, Jason Unrine, Shu Lui, Joseph Rollins, Emma Nienaber, Cassidy Spease, Aggie Williams, Lindsay Cormier
Summary: Our study evaluated the therapeutic dosing, tumor reduction efficacy, and selective distribution of a newly synthesized chemotherapeutic agent, Pt-Mal-LHRH, which targets the LHRH receptor expressed by triple negative breast cancer (TNBC). We found increased LHRH expression in reproductive tissues and Pt-Mal-LHRH showed enhanced platinum accumulation in TNBC tumor tissues compared to carboplatin. Furthermore, Pt-Mal-LHRH exhibited selective targeting of reproductive tissues and significantly attenuated TNBC tumor growth in in-vivo models.
Article
Pharmacology & Pharmacy
Joao Lobo, Ana Rita Cardoso, Vera Miranda-Goncalves, Leendert H. J. Looijenga, Marie Lopez, Paola B. Arimondo, Rui Henrique, Carmen Jeronimo
Summary: The study tested a new synthetic flavonoid compound from the 3-nitroflavanone family on testicular germ cell tumor cell lines, finding that it reduced cell viability, decreased DNMT protein expression, promoted cell differentiation, and caused dysregulation of multiple targets leading to apoptosis and cell cycle arrest.
Article
Biochemistry & Molecular Biology
Lisha Sun, Yixiao Zhang, Guanglei Chen, Yaoting Ji, Qingtian Ma, Xinbo Qiao, Sijin Wu, Lin Zhou, Jiawen Bu, Xudong Zhu, Xiaoying Zhang, Xiaofan Jiang, Chao Liu, Xinnan Li, Yang Liu, Yongliang Yang, Caigang Liu
Summary: The study found an association between SOST expression and breast cancer bone metastases and poor survival rates; SOST silencing significantly reduced the bone metastatic capacity of breast cancer cells, while the interaction of SOST with STAT3 enhanced TGF-beta/KRAS signaling, leading to increased tumor growth and bone metastasis.
Article
Materials Science, Multidisciplinary
Muralidhar Chourashiya, Raghunandan Sharma, Saso Gyergyek, Shuang Ma Andersen
Summary: The PEMFC technology is approaching maturity, but the challenges of insufficient durability and high cost of catalysts need to be addressed for fuel cell vehicles. Recycling platinum from end-of-life fuel cell stacks as a secondary source for Pt/C catalysts is found to be an economically and environmentally viable solution. The electrochemical performances of recycled Pt/C catalysts are comparable to commercial benchmark catalysts.
MATERIALS CHEMISTRY AND PHYSICS
(2022)
Article
Biochemistry & Molecular Biology
Jeong A. Bae, Woo Kyun Bae, Sung Jin Kim, Yoo-Seung Ko, Keon Young Kim, So-Yeon Park, Young Hyun Yu, Eun Ae Kim, Ik Joo Chung, Hangun Kim, Hyung-Ho Ha, Kyung Keun Kim
Summary: The study identified DKC1125 as an effective candidate drug for suppressing distant metastasis in colorectal cancer by disintegrating the KITENIN complex. DKC1125 also restored sensitivity to common chemotherapy drugs, showing promise as a novel therapeutic option for CRC patients with high levels of KITENIN.
Article
Environmental Sciences
Ayla Karatas, Duygu Fatma Can
Summary: The study investigated the effects of compound 2a on the developmental properties of Drosophila melanogaster. The results showed that the compound had a significant impact on the F-2 generation, with an increase in abnormal individuals at the highest dose. This new sulfonamide compound may be a promising therapeutic agent in the future.
FRESENIUS ENVIRONMENTAL BULLETIN
(2021)
Article
Multidisciplinary Sciences
Dilan Boodhai Jaunky, Kevin Larocque, Mathieu C. Husser, Jiang Tian Liu, Pat Forgione, Alisa Piekny
Summary: The new microtubule-destabilizing compound C75 showed cytotoxic effects in human cells, inhibiting microtubule polymerization and causing unique spindle phenotypes different from colchicine. Live imaging revealed that C75 induced multipolar spindles and uneven microtubule regrowth, suggesting a potential mechanism involving blocking microtubule polymerization. Combination of low amounts of C75 with paclitaxel resulted in greater regression of multicellular tumor spheroids, showing promise for further exploration of C75's anti-cancer potential.
SCIENTIFIC REPORTS
(2021)
Article
Plant Sciences
Shunyan Cui, Zhiqiang Mao, Xinxin Hou, Zhaojin Ran, Xuecheng Xin, Tingting Wei, Fan Zhou
Summary: A new compound similar to methyl jasmonate was synthesized and tested for its ability to inhibit pre-harvest sprouting (PHS) in wheat. Exogenously applied compound effectively reduced alpha-amylase activity, delayed PHS, and preserved the vigor of wheat seeds. These findings may contribute to the development of a PHS preventative retardant.
PLANT GROWTH REGULATION
(2022)
Article
Medicine, General & Internal
Mengdi Guo, Qian Cao, Shengnan Xia, Xiang Cao, Jian Chen, Yi Qian, Xinyu Bao, Yun Xu
Summary: This study aimed to investigate the anti-inflammatory effect of a novel lipophilic compound CP-07 in LPS-stimulated cells and primary mouse microglia, as well as its therapeutic effect on ischemia/reperfusion brain injury. The research showed that CP-07 could effectively suppress cytokine production, reduce infarct volume, and promote neurological function recovery.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Namrata Prajapati, Dilip Sharma, Pankaj Ashok Bidve, Deepak Chouhan, Meghana Allani, Sagar Kumar Patel, Moumita Ghosh Chowdhury, Amit Shard, Vinod Tiwari
Summary: Management of type 2 diabetes mellitus using DPP IV inhibitors is important, but current inhibitors have side effects. This study investigates the effect of new boronic acid-based thiazole compounds as DPP IV inhibitors. Two boronic acid-based molecules, PC06R58 and PC06R108, show potent DPP IV enzyme inhibition and significantly reduce blood glucose levels in rats. These compounds have satisfactory DPP IV inhibition and show promise as lead compounds in this novel class of DPP IV inhibitors.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Chemistry, Multidisciplinary
Jun-Nian Zhou, Biao Zhang, Hai-Yang Wang, Dong-Xing Wang, Ming-Ming Zhang, Min Zhang, Xiao-Kui Wang, Shi-Yong Fan, Ying-Chen Xu, Quan Zeng, Ya-Li Jia, Jia-Fei Xi, Xue Nan, Li-Juan He, Xin-Bo Zhou, Song Li, Wu Zhong, Wen Yue, Xue-Tao Pei
Summary: The compound phenyl-2-pyrimidinyl ketone 4-ally)-3-amino selenourea (CU27) shows inhibitory effects on cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) by inhibiting the transcription activity of c-Myc, suggesting its potential as a therapeutic for sorafenib-resistant HCC.
Article
Biochemistry & Molecular Biology
Fatima Ezzahra Bennani, Latifa Doudach, Khalid Karrouchi, Abdelilah Tarib, Christopher E. Rudd, M'hammed Ansar, My El Abbes Faouzi
Summary: This study computationally evaluates the efficacy of 63 in-house synthesized pyrazole derivatives targeting prominent cancer targets. Docking and molecular dynamic simulation studies suggest that certain pyrazole compounds show better binding affinity than standard drugs and exhibit potential as cancer therapeutics. The findings provide insights for future drug development.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Pharmacology & Pharmacy
Fares Hezam Al-Ostoot, Ankith Sherapura, V. Vigneshwaran, Giridhara Basappa, H. K. Vivek, B. T. Prabhakar, Shaukath Ara Khanum
Summary: The study synthesized and validated new IPA (8a-n) analogs, with IPA (8k) identified as a lead molecule with anti-proliferative and anti-angiogenic activities. By targeting HIF-1α, it modulates downstream genes and exhibits anti-tumor activity both in vitro and in vivo.
PHARMACOLOGICAL REPORTS
(2021)
Article
Medicine, Research & Experimental
Xiaojing Zheng, Chunlian Li, Xiang Gao
Summary: This study found that the overexpression of miR-375 counteracts the effects of Dex treatment on AEC viability, migration, invasion, and apoptosis by targeting DUSP6, further demonstrating the important role of miR-375 in AEC dysfunction.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
(2022)
Article
Medicine, General & Internal
Csaba Csikos, Adrienn Vagner, Gabor Nagy, Ibolya Kalman-Szabo, Judit P. Szabo, Minh Toan Ngo, Zoltan Szoboszlai, Dezso Szikra, Zoard Tibor Krasznai, Gyorgy Trencsenyi, Ildiko Garai
Summary: The aim of this study was to evaluate the biodistribution and tumor-targeting potential of Mn-52-labeled DOTAGA-bevacizumab. The VEGF-A targeting potential of the new immuno-PET ligand was assessed using the VEGF-A expressing KB-3-1 (human cervix carcinoma) tumor-bearing CB17 SCID mouse model and in vivo PET/MRI imaging. Due to the high and specific accumulation found in the subcutaneously located experimental cervix carcinoma tumors, [Mn-52]Mn-DOTAGA-bevacizumab is a promising PET probe for the detection of VEGF-A positive gynecological tumors, for patient selection, and monitoring the efficacy of therapies targeting angiogenesis.
